GANX vs GERN

Gain Therapeutics, Inc. vs Geron Corporation — Valuation Comparison 2026

GANX

Biotechnology
Gain Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
32
LOW
Price
$2.02
Last close
Models
7/13
Active
VS

GERN

Biotechnology
Geron Corporation
Quality
4.6
out of 10
Value Trap
26
LOW
Price
$1.25
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType GANX Fair ValueGANX Upside GERN Fair ValueGERN Upside
Bayesian DCF Intrinsic $0.75 -63.0% $0.32 -74.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.47 -76.7% $0.28 -78.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GANX vs GERN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GANX vs GERN — Which Stock Is More Undervalued?

GERN scores higher with a 4.6/10 quality rating vs GANX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Gain Therapeutics, Inc. (GANX) and Geron Corporation (GERN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GANX currently trades at $2.02 with a QOC of 4.3/10, while GERN trades at $1.25 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).